24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Diabetes Treatment Failure May Actually Be NonadherenceArtificial Intelligence Can Detect Diabetic RetinopathyMore Than 1 in 10 Patients May Be Overtreated for DiabetesPioglitazone Has Limited Effect in Lipoatrophic DiabetesFracture Risk Higher for Seniors With DiabetesCGM Use in Pregnancy Improves Neonatal OutcomesClosed-Loop Control Benefits T1DM in Prolonged Winter SportHeath Tip: Dining Out If You Have DiabetesExenatide Doesn't Up Cardiovascular Risk in T2DMIncreasing Salt Intake Tied to Diabetes RiskSotagliflozin Linked to Improved Glycemic Control in T1DMGreater Awareness Needed for Potential of T2DM RemissionCan Coffee or Tea Extend Survival With Diabetes?Could Artificial Sweeteners Raise Your Diabetes Risk?Could Swine Flu Be Linked to Type 1 Diabetes?'Upside' to Diabetes Really Isn'tLifestyle Tips for Better Diabetes ControlDiabetes Threatens Kidneys, Vision of Millions of Americans2017 Standards of Medical Care in Diabetes ReleasedBiomarkers Can Predict Rapid Drop in Renal Function in T2DMMany Teens With Type 1 Diabetes Report Disordered EatingCognitive Test Predicts Elderly Insulin Injection SuccessHigher Event Rate of T2DM in Polycystic Ovary SyndromeNovel Genetic Variant in IGF2 Linked to Reduced T2DM RiskFatty Acid Remodeling Seen in T2DM Remission Post Bariatric SxDiacerein Reduces Mean Hemoglobin A1c Levels in T2DMHealth Tip: Risk Factors for PrediabetesTablet Use Encourages Patients to Explore Diabetes RiskOnce-Yearly Counseling Tied to More Physical Activity in T2DMIn T2D, Glycemic Control Up With Continuous Glucose MonitoringSecure Messaging Linked to Better Diabetes ManagementStudies Often Fail to Include Info on T2DM Medication AdherenceIntensive Blood Pressure Tx Aids Those With PrediabetesLifestyle Intervention Only Offers Modest Benefit in Type 2 DiabetesSleep Duration Inversely Linked to Risk Markers of T2DM in KidsCould Big Lifestyle Changes Be Key to Managing Type 2 Diabetes?Variation in Participation in Diabetes Self-Management ClassTeam-Based Online Game May Improve Glycemic Control in T2DArtificial Sweeteners Trick the Brain: StudyCharacteristics of Diabetes in Infancy ExploredImmunotherapy Shown Safe in Type 1 Diabetes Clinical TrialOnline Game Helps Those With Diabetes Control Blood SugarHeart Health Ignored by Many With Type 2 DiabetesMortality Down Only for Gastric Bypass Patients With DiabetesInstagram Shows How Diabetics Really Wear a Glucose MonitorWhat Diabetics Need to Know About Over-the-Counter MedsEngineered Skin Cells Control Type 2 Diabetes in Mice: StudySimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesDiabetes Symptoms Appear to Spread Via Prion-Like MechanismPoor Adherence to Self-Monitoring of Glucose in GDM
Links
Related Topics

Medical Disorders

Continuous Subcutaneous Insulin Infusion Bests Injections in T2DM


HealthDay News
Updated: Apr 7th 2017

new article illustration

FRIDAY, April 7, 2017 (HealthDay News) -- For patients with type 2 diabetes and hemoglobin A1c (HbA1c) >8 percent following multiple daily injections (MDI), continuous subcutaneous insulin infusion (CSII) is associated with a significantly greater reduction in HbA1c than MDI, according to a study published online April 4 in Diabetes, Obesity and Metabolism.

Muriel Metzger, M.D., from the Diabetes Clinic in Jerusalem, and colleagues examined factors associated with the decrease in HbA1c among patients receiving CSII in the OpT2mise randomized trial. Following MDI optimization, patients with type 2 diabetes and HbA1c >8 percent were randomized to receive six months of CSII (168 patients) or MDI (163 patients).

The researchers found that, compared with MDI, CSII produced a significantly greater reduction in HbA1c; the difference increased with baseline HbA1c. Higher baseline HbA1c, geographical region, higher education level, higher total cholesterol level, lower variability of baseline glucose valued on continuous glucose monitoring, and the decrease in average fasting self-monitored blood glucose at six months were the only factors significantly associated with decreased HbA1c in the CSII arm.

"These findings suggest that CSII offers an option to improve glycemic control in a broad range of type 2 diabetes patients in whom control cannot be achieved with MDI," the authors write.

The study was funded by Medtronic.

Abstract
Full Text (subscription or payment may be required)